Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Type I but Not Type II Calreticulin Mutations Activate the IRE1α/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms.
Ibarra J, Elbanna YA, Kurylowicz K, Ciboddo M, Greenbaum HS, Arellano NS, Rodriguez D, Evers M, Bock-Hughes A, Liu C, Smith Q, Lutze J, Baumeister J, Kalmer M, Olschok K, Nicholson B, Silva D, Maxwell L, Dowgielewicz J, Rumi E, Pietra D, Casetti IC, Catricala S, Koschmieder S, Gurbuxani S, Schneider RK, Oakes SA, Elf SE. Ibarra J, et al. Among authors: ciboddo m. Blood Cancer Discov. 2022 Jul 6;3(4):298-315. doi: 10.1158/2643-3230.BCD-21-0144. Blood Cancer Discov. 2022. PMID: 35405004 Free PMC article.
Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms.
Rumi E, Zibellini S, Boveri E, Cavalloni C, Riboni R, Casetti IC, Ciboddo M, Trotti C, Favaron C, Pietra D, Candido C, Ferretti VV, Cazzola M, Arcaini L. Rumi E, et al. Among authors: ciboddo m. Am J Hematol. 2019 Jul;94(7):E185-E188. doi: 10.1002/ajh.25489. Epub 2019 May 1. Am J Hematol. 2019. PMID: 30972817 Free article. Clinical Trial. No abstract available.
Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNs.
Jutzi JS, Marneth AE, Ciboddo M, Guerra-Moreno A, Jiménez-Santos MJ, Kosmidou A, Dressman JW, Liang H, Hamel R, Lozano P, Rumi E, Doench JG, Gotlib J, Krishnan A, Elf S, Al-Shahrour F, Mullally A. Jutzi JS, et al. Among authors: ciboddo m. Blood. 2022 Sep 15;140(11):1291-1304. doi: 10.1182/blood.2022015629. Blood. 2022. PMID: 35763665 Free PMC article.
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria.
Rumi E, Boveri E, Bellini M, Pietra D, Ferretti VV, Sant'Antonio E, Cavalloni C, Casetti IC, Roncoroni E, Ciboddo M, Benvenuti P, Landini B, Fugazza E, Troletti D, Astori C, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Rumi E, et al. Among authors: ciboddo m. Oncotarget. 2017 Oct 6;8(60):101735-101744. doi: 10.18632/oncotarget.21594. eCollection 2017 Nov 24. Oncotarget. 2017. PMID: 29254200 Free PMC article.
PDGFB hypomethylation is a favourable prognostic biomarker in primary myelofibrosis.
Augello C, Gianelli U, Falcone R, Tabano S, Savi F, Bonaparte E, Ciboddo M, Paganini L, Parafioriti A, Ricca D, Lonati S, Cattaneo D, Fracchiolla NS, Iurlo A, Cortelezzi A, Bosari S, Miozzo M, Sirchia SM. Augello C, et al. Among authors: ciboddo m. Leuk Res. 2015 Feb;39(2):236-41. doi: 10.1016/j.leukres.2014.11.012. Epub 2014 Dec 2. Leuk Res. 2015. PMID: 25498506 Clinical Trial.